Areas of Research
- Stem Cell Biology Research
- Targeted Therapy Research
- Immunity Research
- Immunotherapy Research
- Immunology Research
- Leukemia Research
The investigative focus of the Reisner Laboratory consists of immune tolerance mechanisms in stem cell transplantation and cell therapy. Our research goals are to overcome alloreactivity in mismatched donors, and to improve patient outcomes with hematopoietic stem cell transplantation and cellular immunotherapy. Additionally, we're developing novel strategies for lung regeneration by means of lung stem cell transplantation. Our work is focused on mechanisms of immune-tolerance induction, characterization of lung stem cells and the clinical translation of effective therapies for bone marrow and organ transplantation, immuno-oncology and regenerative medicine.
For more than 30 years, research in the Reisner Laboratory has been involved with the subject of transplantation immunology and, more specifically, with questions relating to stem cell transplantation. Through this, we've translated two major milestones into clinical achievements:
- Transplantation of haploidentical hematopoietic lectin-separated stem cells in SCID patients
- The use of ‘mega dose’ transplants in leukemia patients
More recently, major insights from our work could potentially pave the way for safe hematopoietic stem cell transplantation under reduced conditioning, as a platform for organ transplantation and cell therapy. In parallel to the major drive to improve outcome of transplants, a major aim of our studies addresses mechanisms of tolerance induction by progenitor cells in the bone marrow, and by other tolerizing cells including CD8 veto T cells and MSCs and immature dendritic cells.
During the past 15 years we also extended our interest to transplantation of stem cells from other tissues and organs (Nature Medicine 2003; PNAS 2005; PLOS Med. 2006 ; J. Am. Soc. Nephrol. 2006; PNAS 2006; PNAS 2009) .
Very recently, we described a new curative approach for lung diseases based on transplantation of fetal lung stem cells (Nature Medicine ; 2015) and most recently that of adult lung stem cells (Stem Cell Translation Medicine; 2018). It's hoped that these studies will pave the way for curative transplantation in Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and other lung diseases. Our major basic research studies aim to characterize the lung stem cells used in our transplantation procedure.
Yair Reisner, Ph.D.
Professor, Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
Director, Stem Cell Research